Drug Profile
Sebetralstat - KalVista Pharmaceuticals
Alternative Names: KVD-900Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Amines; Aza compounds; Esters; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hereditary angioedema
Most Recent Events
- 12 Mar 2024 KalVista Pharmaceuticals receives Promising Innovative Medicine (PIM) designation from UK Medicines and Healthcare products Regulatory Agency (MHRA) for sebetralstat in hereditary angioedema
- 11 Mar 2024 KalVista Pharmaceuticals plans to file for regulatory approval of sebetralstat for Hereditary angioedema in the EU and Japan in 2024
- 11 Mar 2024 KalVista Pharmaceuticals plans to submit an NDA to the US FDA for Hereditary angioedema in USA, in the first half of 2024